1-20 of 124
Katja Weisel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Temporal Evolution of Chromosome 1q Gain and Hyperdiploidy and Its Impact on Clinical Outcomes in Multiple Myeloma

Francesco Maura, Marcella Kaddoura, Alexandra Maria Poos, Anthony Cirrincione, Benjamin Diamond, Kylee H Maclachlan, Bachisio Ziccheddu, Elias K. Mai, Hartmut Goldschmidt, Katja Weisel, Roland Fenk, Gareth J. Morgan, Saad Z Usmani, Ola Landgren, Marc S. Raab, Niels Weinhold
Journal: Blood
Blood (2023) 142 (Supplement 1): 638.
https://doi.org/10.1182/blood-2023-182267
Published: 2023
Journal Articles

Spatial Dissection of the Bone Marrow Microenvironment in Multiple Myeloma By High Dimensional Multiplex Tissue Imaging

Marc-Andrea Baertsch, Alexander Brobeil, John Hickey, Maximilian Haist, Alexandra Maria Poos, Guolan Lu, Wilson Kuswanto, Christian Schuerch, Harald Voehringer, Wolfgang Huber, Gunhild Mechtersheimer, Carsten Mueller-Tidow, Peter Schirmacher, Katja Weisel, Roland Fenk, Hartmut Goldschmidt, Yury Goltsev, Marc S. Raab, Niels Weinhold, Garry P. Nolan
Journal: Blood
Blood (2023) 142 (Supplement 1): 85.
https://doi.org/10.1182/blood-2023-189255
Published: 2023
Journal Articles

Outcomes of Patients with Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from the LocoMMotion + MoMMent Studies

Philippe Moreau, Maria-Victoria Mateos, Hartmut Goldschmidt, Esther Gonzalez Garcia, Britta Besemer, Marta Sonia Gonzalez Perez, Mohamad Mohty, Joanne Lindsey-Hill, Suriya Kirkpatrick, Michel Delforge, Emanuele Angelucci, Francesco Di Raimondo, Ravi Vij, Margaret Doyle, Kathleen Gray, Claire Albrecht, Vadim Strulev, Imène Haddad, Silva Saarinen, Lada Mitchell, Jozefien Buyze, Katja Weisel
Journal: Blood
Blood (2023) 142 (Supplement 1): 4698.
https://doi.org/10.1182/blood-2023-181235
Published: 2023
Journal Articles

Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel Vs Standard of Care in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Lines of Therapy

Roberto Mina, Anne K Mylin, Hisayuki Yokoyama, Hila Magen, Winfried Alsdorf, Monique C Minnema, Leyla Shune, Iris Isufi, Simon J. Harrison, Urvi A Shah, Jordan M. Schecter, Nikoletta Lendvai, Katharine S Gries, Eva G Katz, Ana Slaughter, Carolina Lonardi, Jane Gilbert, Quanlin Li, William Deraedt, Octavio Costa Filho, Nitin Patel, Lionel Karlin, Katja Weisel
Journal: Blood
Blood (2023) 142 (Supplement 1): 1063.
https://doi.org/10.1182/blood-2023-178798
Published: 2023
Journal Articles

Revealing Novel Mechanisms Underlying Inactivation of Tumor Suppressor Genes on Duplicated Chromosomes in Multiple Myeloma

Anthony Cirrincione, Marcella Kaddoura, Alexandra Maria Poos, Bachisio Ziccheddu, Kylee H Maclachlan, Monika Chojnacka, Benjamin Diamond, Patrick Blaney, Dylan Gagler, Yanming Zhang, Ahmet Dogan, Alexander Lesokhin, Faith E. Davies, Hartmut Goldschmidt, Katja Weisel, Roland Fenk, Elias K. Mai, Neha Korde, Gareth J. Morgan, Marc S. Raab, Saad Z Usmani, Ola Landgren, Niels Weinhold, Francesco Maura
Journal: Blood
Blood (2023) 142 (Supplement 1): 874.
https://doi.org/10.1182/blood-2023-186802
Published: 2023
Journal Articles

Immunological Subgroups Predicting Efficacy of Elotuzumab in Multiple Myeloma Patients: Insights from the GMMG-HD6 Clinical Trial

Gigi Nu Hoang Quy Ton, Katharina Kriegsmann, Mohamed H.S. Awwad, Axel Benner, Uta Bertsch, Britta Besemer, Mathias Hänel, Roland Fenk, Jana Schlenzka, Markus Munder, Jan Dürig, Igor Wolfgang Blau, Stefanie Huhn, Dirk Hose, Anna Jauch, Andreas Neubauer, Niels Weinhold, Christof Scheid, Roland Schroers, Ivana von Metzler, Aneta Schieferdecker, Jörg Thomalla, Peter Reimer, Rolf Mahlberg, Ullrich Graeven, Stephan Kremers, Uwe Martens, Christian Kunz, Manfred Hensel, Andrea Seidel-Glätzer, Katja Weisel, Hans Salwender, Carsten Müller-Tidow, Marc S. Raab, Hartmut Goldschmidt, Elias K. Mai, Michael Hundemer
Journal: Blood
Blood (2023) 142 (Supplement 1): 1991.
https://doi.org/10.1182/blood-2023-189169
Published: 2023
Journal Articles

The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)

Jens Hillengass, Adam D. Cohen, Mounzer E Agha, Michel Delforge, Tessa Kerre, Wilfried Roeloffzen, Hermann Einsele, Hartmut Goldschmidt, Katja Weisel, Marc S. Raab, Christof Scheid, Sebastien Anguille, Pieter Sonneveld, Sonja Zweegman, Jordan M. Schecter, Kevin C De Braganca, Carolyn Chang Jackson, Philip Vlummens, Helen Varsos, Christina Corsale, Deepu Madduri, Tzu-min Yeh, Pankaj Mistry, Tito Roccia, Qingxuan Song, Muhammad Akram, Octavio Costa Filho, Dong Geng, Yael C. Cohen, Niels W.C.J. Van De Donk
Journal: Blood
Blood (2023) 142 (Supplement 1): 1021.
https://doi.org/10.1182/blood-2023-178882
Published: 2023
Journal Articles

Updated Safety and Efficacy Results of Abbv-383, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in a First-in-Human Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma

Ravi Vij, Shaji Kunnathu Kumar, Anita D'Souza, John T Mckay, Peter M. Voorhees, Alfred Chung, Sascha Alexander Tuchman, Neha Korde, Katja Weisel, Raphael Teipel, Orlando Bueno, Zhongling Feng, Tanya S Rosenberg, Rajvineeth Kumar Pothacamury, Akshanth R Polepally, Shane Lee, Ziyi Jin, Jeremy A Ross, Aarif Ahsan, Chetasi Talati, Cesar Rodriguez
Journal: Blood
Blood (2023) 142 (Supplement 1): 3378.
https://doi.org/10.1182/blood-2023-182388
Published: 2023
Journal Articles

Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients

Francesca Gay, Wilfried Roeloffzen, Meletios A. Dimopoulos, Laura Rosiñol, Marjolein van der Klift, Roberto Mina, Albert Oriol Rocafiguera, Eirini Katodritou, Ka Lung Wu, Paula Rodriguez Otero, Roman Hajek, Elisabetta Antonioli, Mark van Duin, Mattia D'Agostino, Joaquin Martinez-Lopez, Elena M. van Leeuwen-Segarceanu, Paola Tacchetti, Niels W.C.J. van de Donk, Katja Weisel, Luděk Pour, Jakub Radocha, Angelo Belotti, Fredrik Schjesvold, Joan Bladé, Hermann Einsele, Pieter Sonneveld, Mario Boccadoro, Annemiek Broijl
Journal: Blood
Blood (2023) 142 (Supplement 1): 4.
https://doi.org/10.1182/blood-2023-177546
Published: 2023
Journal Articles

Impact of Long-Term Treatment with Belantamab Mafodotin on Safety and Efficacy Outcomes in Patients with Relapsed/Refractory Multiple Myeloma in DREAMM-3

Vania T.M Hungria, Katja Weisel, Atanas Radinoff, Sosana Delimpasi, Gabor Mikala, Tamas Masszi, Jian Li, Marcelo Capra, Angelo Maiolino, Vasiliki Pappa, Dominik Chraniuk, Iurii Osipov, Xavier Leleu, Michael Low, Morio Matsumoto, Mary Li, Neal Sule, Margaret Polinkovsky, Randy Davis, Shelley Bright, Astrid McKeown, Joanna Opalinska, Meletios Athanasios Dimopoulos
Journal: Blood
Blood (2023) 142 (Supplement 1): 3357.
https://doi.org/10.1182/blood-2023-178009
Published: 2023
Journal Articles

Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Long Term Follow up Results of the Randomized GMMG Phase III Multicenter Trial Relapse

Marc-Andrea Baertsch, Jana Schlenzka, Thomas Hielscher, Marc S. Raab, Sandra Sauer, Maximilian Merz, Elias K. Mai, Carsten Müller-Tidow, Steffen Luntz, Anna Jauch, Peter Brossart, Martin Goerner, Stefan Klein, Bertram Glass, Peter Reimer, Ullrich Graeven, Roland Fenk, Mathias Hänel, Ivana von Metzler, Lindemann Hans W., Christof Scheid, Axel Nogai, Hans Salwender, Richard Noppeney, Britta Besemer, Katja Weisel, Hartmut Goldschmidt
Journal: Blood
Blood (2023) 142 (Supplement 1): 782.
https://doi.org/10.1182/blood-2023-178835
Published: 2023
Journal Articles

Pharmacokinetics and Immunogenicity of Abbv-383, a B-Cell Maturation Antigen (BCMA) × CD3 Bispecific T-Cell-Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Akshanth R Polepally, Carla Biesdorf, Muhammad Erfan Uddin, Nils Boehm, Jeremy A Ross, Shaji Kunnathu Kumar, Peter M. Voorhees, Anita D'Souza, Katja Weisel, Orlando Bueno, Chetasi Talati, Rajeev M Menon
Journal: Blood
Blood (2023) 142 (Supplement 1): 6722.
https://doi.org/10.1182/blood-2023-180127
Published: 2023
Journal Articles

A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAF V600E -mutated multiple myeloma

Clinical Trials & Observations Brief Report
Nicola Giesen, Manik Chatterjee, Christof Scheid, Alexandra M. Poos, Britta Besemer, Kaya Miah, Axel Benner, Nicole Becker, Thomas Moehler, Ivana Metzler, Cyrus Khandanpour, Andrea Seidel-Glaetzer, Karolin Trautmann-Grill, K. Martin Kortüm, Carsten Müller-Tidow, Gunhild Mechtersheimer, Benjamin Goeppert, Albrecht Stenzinger, Niels Weinhold, Hartmut Goldschmidt, Katja Weisel, Marc S. Raab
Journal: Blood
Blood (2023) 141 (14): 1685–1690.
https://doi.org/10.1182/blood.2022017789
Published: 2023
Includes: Supplemental data
Journal Articles

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma: Planned Interim Analysis of the GMMG-Concept Trial

Katja Weisel, Britta Besemer, Mathias Haenel, Raphael Lutz, Christoph Mann, Markus Munder, Martin Goerner, Hans Christian Reinhardt, Axel Nogai, Yon-Dschun Ko, Maike De Wit, Hans Salwender, Christoph Scheid, Ullrich Graeven, Rudolf Peceny, Peter Staib, Annette Dieing, Anna Jauch, Manola Zago, Axel Benner, Diana Tichy, Carsten Bokemeyer, Hartmut Goldschmidt, Lisa B. Leypoldt
Journal: Blood
Blood (2022) 140 (Supplement 1): 1836–1838.
https://doi.org/10.1182/blood-2022-156309
Published: 2022
Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study

Shaji K Kumar, Philippe Moreau, Nizar Jacques Bahlis, Thierry Facon, Torben Plesner, Robert Z. Orlowski, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Katja Weisel, Noopur Raje, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Maria Krevvata, Robin Carson, Fredrik Borgsten, Saad Usmani
Journal: Blood
Blood (2022) 140 (Supplement 1): 10150–10153.
https://doi.org/10.1182/blood-2022-163335
Published: 2022
Journal Articles

Implications and Prognostic Impact of Mass Spectrometry in Patients with Newly-Diagnosed Multiple Myeloma

Elias K Mai, Stefanie Huhn, Kaya Miah, Alexandra M Poos, Christof Scheid, Katja Weisel, Uta Bertsch, Markus Munder, Oscar Berlanga, Dirk Hose, Anja Seckinger, Anna Jauch, Igor Wolfgang Blau, Mathias Haenel, Hans Salwender, Axel Benner, Marc S Raab, Hartmut Goldschmidt, Niels Weinhold
Journal: Blood
Blood (2022) 140 (Supplement 1): 2341–2343.
https://doi.org/10.1182/blood-2022-156169
Published: 2022
Journal Articles

Dose Escalation and Expansion of Abbv-383 in Combination with Anti-Cancer Regimens in Relapsed or Refractory Multiple Myeloma

Cesar Rodriguez, Katja Weisel, Rachid C. Baz, Akshanth R. Polepally, Jeremy A. Ross, Ziyi Jin, Kristin D'Amico, Orlando F. Bueno, Leanne Lash Fleming, Peter M. Voorhees
Journal: Blood
Blood (2022) 140 (Supplement 1): 7326–7327.
https://doi.org/10.1182/blood-2022-157977
Published: 2022
Journal Articles

A Phase 1 First-in-Human Study of Abbv-383, a BCMA × CD3 Bispecific T-Cell-Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma

Peter M. Voorhees, Anita D'Souza, Katja Weisel, David Duane Hurd, Raphael Teipel, Alfred Chung, Cesar Rodriguez, Sascha A. Tuchman, Neha Korde, Hana Safah, Orlando F. Bueno, Neil Pumford, Tanya S Rosenberg, Rajvineeth Kumar Pothacamury, Jeremy A. Ross, Akshanth R. Polepally, Shane Lee, Ziyi Jin, Chetasi Talati, Ravi Vij, Shaji K Kumar
Journal: Blood
Blood (2022) 140 (Supplement 1): 4401–4404.
https://doi.org/10.1182/blood-2022-167008
Published: 2022
Journal Articles

Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial

Aurore Perrot, Thierry Facon, Torben Plesner, Saad Usmani, Shaji K Kumar, Nizar Jacques Bahlis, Cyrille Hulin, Robert Z. Orlowski, Hareth Nahi, Peter Mollee, Karthik Ramasamy, Murielle Roussel, Arnaud Jaccard, Michel Delforge, Lionel Karlin, Bertrand Arnulf, Ajai Chari, Huiling Pei, Niodita Gupta, Shuchita Kaila, Kathryn Matt, Katharine S. Gries, Robin Carson, Fredrik Borgsten, Katja Weisel
Journal: Blood
Blood (2022) 140 (Supplement 1): 1142–1145.
https://doi.org/10.1182/blood-2022-165524
Published: 2022
Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study

Philippe Moreau, Thierry Facon, Saad Usmani, Nizar Jacques Bahlis, Noopur Raje, Torben Plesner, Robert Z. Orlowski, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Katja Weisel, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Maria Krevvata, Robin Carson, Fredrik Borgsten, Shaji K Kumar
Journal: Blood
Blood (2022) 140 (Supplement 1): 7297–7300.
https://doi.org/10.1182/blood-2022-163494
Published: 2022